Lettuce-Delivered GLP-1s: A Potential Game Changer for Diabetes and Obesity Treatment

Glucagon-like peptide-1 (GLP-1) receptor agonists have rapidly become a focal point in the treatment of both type 2 diabetes and obesity. While highly effective, current delivery methods – primarily injections – and manufacturing costs present significant barriers to widespread employ. Now, a latest approach utilizing genetically engineered lettuce chloroplasts offers a promising solution: oral delivery of these crucial medications, potentially at a lower cost and with improved patient compliance.

The Challenge of GLP-1 Delivery

GLP-1 receptor agonists operate by stimulating insulin release and suppressing glucagon secretion, helping to regulate blood sugar levels. They as well reduce appetite and slow gastric emptying, contributing to weight loss Cleveland Clinic. However, delivering these peptide-based drugs orally has been historically difficult. The digestive system breaks down peptides, hindering their absorption in the gut. Existing oral formulations, like oral semaglutide (Ozempic®), require strict fasting and timing protocols to maximize effectiveness, and can still cause gastrointestinal side effects like nausea and diarrhea.

Plant-Based Delivery: A Novel Approach

Researchers at the University of Pennsylvania, led by Henry Daniell, have pioneered a novel solution: genetically engineering lettuce chloroplasts to produce and protect GLP-1 peptides JAMA Network. This method leverages the natural protective properties of plant cells. “We eat plant cells all the time,” explains Daniell. “And we deliberately chose exenatide and lixisenatide because they have been used very successfully in the clinic and have a long safety record.”

By incorporating the GLP-1 therapies into the lettuce genome, the peptides are shielded from degradation in the stomach. When the lettuce cells reach the gut, bacteria break down the cell walls, releasing the functional GLP-1 peptides for absorption. This approach also bypasses the need for post-translational modifications – chemical changes required to make the peptides functional – as plant cells naturally perform these modifications.

Benefits of Plant-Encapsulated GLP-1s

• Improved Delivery: Protects peptides from stomach acid and enhances gut absorption.
• Reduced Side Effects: Utilizing natural versions of the peptides may lower the risk of gastrointestinal issues, which are often associated with synthetic GLP-1s.
• Lower Cost: The simplified production process, utilizing readily available lettuce, has the potential to significantly reduce manufacturing costs.
• Enhanced Safety: Exenatide and lixisenatide have established safety profiles with decades of clinical use.

Current Status and Future Directions

The research team is now focused on scaling up production of their plant-encapsulated GLP-1 receptor agonists, building on their experience with oral insulin production. They have the facilities to produce materials for early-stage clinical trials FDA. The team is also investigating the potential of this delivery platform for other peptide-based therapies.

Key Takeaways

• A new method for delivering GLP-1 receptor agonists orally using genetically engineered lettuce chloroplasts shows promise.
• This approach could overcome barriers to widespread GLP-1 use, including injection aversion, high costs, and side effects.
• Further research and clinical trials are needed to confirm the efficacy and safety of this innovative delivery system.